Trigone Pharma Ltd. is a privately-held specialty pharmaceutical company focused on the development of a proprietary sustained-release platform designed to enhance the efficacy and safety of ...

Relmada Therapeutics announced a licensing agreement for NDV-01, a new treatment for non-muscle invasive bladder cancer. Phase 2 data expected in April 2025. Relmada Therapeutics, Inc. has announced ...

NDV-01 is a novel, sustained-release, intravesical gemcitabine/docetaxel, ready-for-use product candidate for the treatment of non-muscle invasive bladder cancer ...